SCHEMBL4187947

SCHEMBL4187947

O=C1c2cccc3cccc(c23)C(=O)N1CCCO

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HEXA P06865 6/20 0.81
HEXB P07686 6/20 0.81
KMT2A Q03164 4/20 0.69
MEN1 O00255 3/20 0.69
POLB P06746 2/20 0.65
NR1I2 O75469 1/20 0.65
AHR P35869 1/20 0.65
RAD52 P43351 1/20 0.65
RCE1 Q9Y256 1/20 0.65
ALDH1A1 P00352 5/20 0.64
KDM4E B2RXH2 5/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
HTT P42858 2/20 0.64
RECQL P46063 2/20 0.64
RAB9A P51151 2/20 0.64
RGS12 O14924 1/20 0.64
NPC1 O15118 1/20 0.64
LMNA P02545 1/20 0.64
PABPC1 P11940 1/20 0.64
SIRT1 Q96EB6 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7329487 0.95 HEXA (0.78) HEXAHEXBKMT2AMEN1POLB
SCHEMBL11678428 0.93 HEXA (0.76) HEXAHEXBKMT2AMEN1POLB
SCHEMBL11807201 0.93 HEXA (0.76) HEXAHEXBKMT2AMEN1POLB
SCHEMBL4997995 0.89 HEXA (1.00) HEXAHEXBKMT2AMEN1POLB
SCHEMBL9626265 0.89 HEXA (0.83) HEXAHEXBKMT2AMEN1POLB
SCHEMBL9290382 0.89 HEXA (0.64) HEXAHEXBKMT2AMEN1POLB
SCHEMBL9625779 0.87 HEXA (0.81) HEXAHEXBKMT2AMEN1POLB
SCHEMBL9625535 0.87 HEXA (0.81) HEXAHEXBKMT2AMEN1POLB
SCHEMBL9625518 0.87 HEXA (0.81) HEXAHEXBKMT2AMEN1POLB
SCHEMBL9625395 0.87 HEXA (0.81) HEXAHEXBKMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107698571-B Naphthalimide-coumarin DNA targeting double-intercalator, synthesis and application thereof 大连理工大学 2020-07-14 CN claimed
CN-107698571-A Naphthalimide-coumarin DNA targeting double-intercalator, synthesis and application thereof 大连理工大学 2018-02-16 CN claimed
US-4006238-A Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents E. R. SQUIBB & SONS, INC. (US) 1977-02-01 US claimed
US-20220143005-A1 NAPHTHALIMIDE DERIVATIVES AS ANTI-PARASITIC AGENTS FOR THE TREATMENT OF LEISHMANIASIS AS WELL AS VIRAL, BACTERIAL AND NEOPLASTIC DISEASES ISTANBUL MEDIPOL UNIVERSITESI (TR) 2022-05-12 US disclosed
EP-3902788-A1 NAPHTHALIMIDE DERIVATIVES AS ANTI-PARASITIC AGENTS FOR THE TREATMENT OF LEISHMANIASIS AS WELL AS VIRAL, BACTERIAL AND NEOPLASTIC DISEASES Istanbul Medipol Universitesi (TR) 2021-11-03 EP disclosed
CN-107698571-B Naphthalimide-coumarin DNA targeting double-intercalator, synthesis and application thereof 大连理工大学 2020-07-14 CN disclosed
WO-2020139291-A1 NAPHTHALIMIDE DERIVATIVES AS ANTI-PARASITIC AGENTS FOR THE TREATMENT OF LEISHMANIASIS AS WELL AS VIRAL, BACTERIAL AND NEOPLASTIC DISEASES ISTANBUL MEDIPOL UNIVERSITESI (TR) 2020-07-02 WO disclosed
CN-110931583-A Packaging material and module structure 财团法人工业技术研究院 2020-03-27 CN disclosed
US-20200098940-A1 ENCAPSULATION MATERIAL AND MODULE STRUCTURE INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2020-03-26 US disclosed
CN-108727264-A The preparation method and combinations thereof of naphthalimide diester fluorescent dye 斯佩特罗尼克斯公司 2018-11-02 CN disclosed
WO-2018106200-A1 ORIGINAL DRUG MOLECULES FOR THE TREATMENT OF PARASITIC AND NEOPLASTIC DISEASES AND METHODS FOR PREPARATION THEREOF T.C MEDİPOL ÜNİVERSİTESİ (TR) 2018-06-14 WO disclosed
EP-2029545-A2 BISNAPHTHALIMIDOPROPYL DERIVATIVE COMPOUNDS WITH ANTI-PARASITE AND ANTI-CANCER ACTIVITY Universidade Do Porto (PT) 2009-03-04 EP disclosed
WO-2008007262-A2 BISNAPHTHALIMIDOPROPYL DERIVATIVE COMPOUNDS WITH ANTI-PARASITE AND ANTI-CANCER ACTIVITY UNIVERSIDADE DO PORTO (PT) 2008-01-17 WO disclosed
US-5747206-A Electrophotographic photoreceptor FUJI XEROX CO., LTD. (JP) 1998-05-05 US disclosed
WO-1995013817-A1 ENDOTHELIN CONVERTING ENZYME INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1995-05-26 WO disclosed
US-4077958-A ANTIDEPRESSANTS E. R. SQUIBB & SONS, INC. (US) 1978-03-07 US disclosed
US-4007191-A ANTIDEPRESSANT E. R. SQUIBB & SONS, INC. (US) 1977-02-08 US disclosed
US-4006238-A Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents E. R. SQUIBB & SONS, INC. (US) 1977-02-01 US disclosed
US-3940397-A ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1976-02-24 US disclosed
US-3935227-A ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143005-A1 NAPHTHALIMIDE DERIVATIVES AS ANTI-PARASITIC AGENTS FOR THE TREATMENT OF LEISHMANIASIS AS WELL AS VIRAL, BACTERIAL AND NEOPLASTIC DISEASES NPM1, ECI1, IPO5 HEXA 2765/4885HEXB 2886/4885KMT2A 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.